Please assess the completion status of the following clinical trial:

Trial Title: Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Cytologically or histologically confirmed solid tumor malignancy for which no curative therapy exists~  * Metastatic disease~* Measurable or evaluable disease (i.e., elevated CA-125 or elevated PSA for patients with ovarian cancer or prostate cancer, respectively)~* Disease amenable to biopsy AND patient willing to undergo biopsies (for patients enrolled in the dose expansion cohort only)~* No uncontrolled CNS metastasis~  * Stable CNS metastasis allowed provided patient has undergone complete surgical resection, gamma knife radiotherapy (for isolated lesions) or whole-brain radiotherapy AND the metastasis has been stable for ≥ 6 weeks~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* WBC \> 3,000/mm³~* ANC \> 1,500/mm³~* Hemoglobin \> 9.0 g/dL (RBC transfusion allowed)~* Platelet count \> 100,000/mm³~* AST/ALT ≤ 1.5 times upper limit of normal (ULN)~* Serum bilirubin ≤ 1.3 times ULN~* Serum creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 50 mL/min by 24-hour urine collection~* Total serum calcium (corrected for serum albumin) or ionized calcium ≥ lower limit of normal~* Serum potassium ≥ 4.0 mEq/L (supplementation allowed)~* Serum magnesium normal (supplementation allowed)~* Serum sodium ≥ 130 mEq/L~* Serum albumin ≥ 3 g/dL~* Elevated alkaline phosphatase or gamma-glutamyl-transferase due to bone metastasis or liver metastasis allowed~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective double-method (including barrier) contraception during and for 3 months after completion of study treatment~* QTc \< 460 ms~* No evidence of significant active infection (e.g., pneumonia, cellulitis, or wound abscess)~* No impaired cardiac function, including any of the following:~  * Complete left bundle branch block or use of a permanent cardiac pacemaker~ * Congenital long QT syndrome~ * History or presence of ventricular tachyarrhythmias~ * Clinically significant resting bradycardia (\< 50 beats per minute)~ * QTcF \> 470 msec on screening ECG~ * Right bundle branch block plus left anterior hemiblock (bifascicular block)~ * Atrial fibrillation (ventricular heart rate \> 100 beats per minute)~ * Angina pectoris or acute myocardial infarction within the past 6 months~ * New York Heart Association class III-IV congestive heart failure~ * LVEF \< 50% on baseline MUGA or ECHO~* No history of seizures~PRIOR CONCURRENT THERAPY:~* No prior cumulative anthracycline dose \> 300 mg/m² of doxorubicin hydrochloride or \> 480 mg/m² of epirubicin hydrochloride~* More than 5 days since prior valproic acid~* More than 3 weeks since prior and no other concurrent chemotherapy, hormonal therapy, radiotherapy, or experimental anticancer therapy for the primary disease~* No other concurrent HDAC inhibitors~* No concurrent medications that may induce torsades de pointes or cause QTc prolongation~* No other concurrent investigational or anticancer therapy~* No concurrent CYP3A4 inhibitors (including grapefruit or grapefruit juice) and/or CYP3A4 inducers~* No concurrent anti-arrhythmic therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- treatment with Panobinostat and Epirubicin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete